key: cord-0707769-qmbtsbya authors: Akama‐Garren, Elliot H.; Li, Jonathan X. title: Prior immunosuppressive therapy is associated with mortality in COVID‐19 patients: A retrospective study of 835 patients date: 2021-06-02 journal: J Med Virol DOI: 10.1002/jmv.27105 sha: ff185e192262771088d50e098b8625ba12680707 doc_id: 707769 cord_uid: qmbtsbya Though it is widely believed that chronic immunosuppressive medications increase the severity of coronavirus disease 2019 (COVID‐19) illness, there is little data to support this. We performed a retrospective study of COVID‐19 positive patients diagnosed at a single academic medical center between March 10, 2020 and October 13, 2020. A total of 835 patients diagnosed with COVID‐19 by polymerase chain reaction were included (median age 64 years; 52% female). Of these, 46 (5.5%) had a prescription for an immunosuppressive therapy before diagnosis, most commonly oral steroids (20, 43%), mycophenolate (12, 26%), or tacrolimus (11, 24%). Patients on immunosuppressive therapy with COVID‐19 had increased mortality (30% vs. 17%, p = 0.036; odds ratio 2.1, 95% confidence interval 1.11–4.04), which remained significant (p = 0.040) after performing multivariate logistic regression controlling for gender, age, race, and comorbidity status. Laboratory markers of inflammation were uniformly elevated in both patients on or not on immunosuppressive therapies who died, but lymphocytes and neutrophils were decreased in both COVID‐19 patients on immunosuppressive therapies who died and who remained alive. These findings demonstrate that COVID‐19 disease is more severe in patients taking prior immunosuppressive medications. This finding emphasizes the need for aggressive monitoring and supportive care for immunosuppressed patients who are diagnosed with COVID‐19. Early clinical studies 1,2 demonstrated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to a severe respiratory illness, with ensuing intensive care unit admission and high mortality. More recent analyses have raised concern that aberrant inflammation is present in a subgroup of patients with severe coronavirus disease 2019 and is a major contributor to mortality. [3] [4] [5] [6] [7] Retrospective studies describing an inflammatory cytokine profile in patients with severe COVID-19, 8, 9 as well as reports of a rare but detrimental multisystem inflammatory syndrome in children with COVID-19, 10 have implicated immune dysregulation in disease severity. Characterization of the immune system in patients with severe versus mild COVID-19, as well as the potential mechanisms by which aberrant inflammation can lead to the severe respiratory illness associated with severe COVID-19, is necessary. Immunosuppression is considered a risk factor for SARS-CoV-2 infection, but the implications of prior immunosuppressive therapies after a patient has become infected remain unclear. 4, 11, 12 Early case studies of patients on disease-modifying antirheumatic drugs (DMARDs) or immunosuppressive therapy with COVID-19 revealed that the majority of patients only develop mild disease. 13, 14 Patients with rheumatic disease on prior DMARD therapy who contracted COVID-19 had varying disease severity that was associated with both known risk factors and rheumatic disease severity. 15, 16 These early observations in both adults with severe COVID-19 and children suggest that aberrant inflammatory responses might be responsible for the high mortality observed in patients with severe COVID-19. It has therefore been proposed that prior immunosuppressive therapies might paradoxically improve outcomes in an inpatient setting, 12 although the relative role of immunosuppressive therapy in early versus late disease and its impact on COVID-19 outcomes remain unknown. Clinical management of immunosuppressed patients with COVID-19, including HIV patients, 17 solid organ transplant recipients, 18 patients undergoing irradiation or taking chemotherapy, 19 and patients with primary immunodeficiencies, 20,21 is currently undergoing continual reevaluation. Small observational studies 13, [22] [23] [24] [25] and recent randomized control trials 26 on immunosuppressive therapy who died have an even greater degree of lymphopenia, which has also been associated with severe COVID-19. 11, 41 Together these results suggest that immunosuppressive therapy both hinders adaptive immune responses and does not prevent hyperinflammation, both of which likely contribute to COVID-19 severity. 3, 4, 11 These findings illustrate the importance of considering mechanisms when implementing immunosuppressive agents for COVID-19 therapy. We also observed that age was not correlated with length of 44 However, we expect both of these sampling biases to affect patients on and not on immunosuppressive therapy similarly, and therefore not influence the increased mortality rate observed in patients with COVID-19 on immunosuppressive therapy. We also did not observe significant associations between prior antirheumatic therapy with mortality in patients with COVID-19, which is consistent with other observational studies, 22 Here, we find that patients on immunosuppressive therapy with COVID-19 are not only at increased risk of dying but also remain susceptible to the inflammation observed in severe COVID-19. As the number of individuals with COVID-19 continues to rise, the number of patients on immunosuppressive therapy who contract COVID-19 will increase as well, and these findings emphasize the importance of aggressive early monitoring and supportive care in this population. More broadly, these findings illustrate the complexities of the role of the immune system in COVID-19 pathogenesis and illustrate the need to recognize these nuances when considering immunomodulatory therapies for COVID-19. We would like to thank S. Li and K. Pollick of the BIDMC InSIGHT CORE service for their assistance with data retrieval. This study was supported by the National Institutes of Health [T32GM007753 to E.A.G.]. Clinical and immunological features of severe and moderate coronavirus disease 2019 Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China COVID-19: consider cytokine storm syndromes and immunosuppression The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19 Cytokine storms: understanding COVID-19 Imbalanced host response to SARS-CoV-2 drives development of COVID-19 Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection -United Kingdom and United States Multisystem inflammatory syndrome in U.S. children and adolescents Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? The Lancet Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression COVID-19 in rheumatic disease patients on immunosuppressive agents Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry Characteristics, comorbidities, and outcomes in a multicenter registry of patients with HIV and coronavirus disease-19 Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: a retrospective cohort Treating the SARS-CoV-2-positive patient with cancer: a proposal for a pragmatic and transparent ethical process Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City Coronavirus disease 2019 in patients with inborn errors of immunity: an international study COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during redzone declaration Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies COVID-19 in persons with multiple sclerosis treated with ocrelizumab: a pharmacovigilance case series Tocilizumab in patients hospitalized with COVID-19 pneumonia Efficacy of tocilizumab in patients hospitalized with COVID-19 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs Viral and host factors related to the clinical outcome of COVID-19 Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a metaanalysis RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19: preliminary report Viral dynamics in mild and severe cases of COVID-19 Association of viral load with serum biomakers among COVID-19 cases Dexamethasoneinduced immunosuppression: mechanisms and implications for immunotherapy The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Host-viral infection maps reveal signatures of severe COVID-19 patients A single-cell atlas of the peripheral immune response in patients with severe COVID-19 Dysregulation of immune response in patients with coronavirus 2019 (COVID-19 Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review Trends in COVID-19 riskadjusted mortality rates Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study